{"id":61264,"date":"2026-03-25T15:20:02","date_gmt":"2026-03-25T07:20:02","guid":{"rendered":"https:\/\/flcube.com\/?p=61264"},"modified":"2026-03-25T15:20:03","modified_gmt":"2026-03-25T07:20:03","slug":"gan-lees-bonfaglutide-wins-nmpa-approval-for-osa-study-biweekly-glp-1-expands-to-sleep-apnea-indication","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61264","title":{"rendered":"Gan & Lee’s Bonfaglutide Wins NMPA Approval for OSA Study \u2013 Biweekly GLP\u20111 Expands to Sleep Apnea Indication"},"content":{"rendered":"\n

Gan & Lee Pharmaceuticals<\/strong> (SHA: 603087<\/a>) announced NMPA clinical trial approval<\/strong> to initiate a study evaluating bonfaglutide<\/strong>, its once\u2011every\u2011two\u2011weeks GLP\u20111 receptor agonist<\/strong>, for moderate\u2011to\u2011severe obstructive sleep apnea (OSA)<\/strong> in adult patients with obesity<\/strong> \u2013 expanding the biweekly injectable’s indication portfolio<\/strong> beyond obesity\/weight management and type 2 diabetes<\/strong> into the high\u2011unmet\u2011need sleep disorder market<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Product<\/strong><\/td>Bonfaglutide \u2013 GLP\u20111 receptor agonist (GLP\u20111RA)<\/td><\/tr>
Company<\/strong><\/td>Gan & Lee Pharmaceuticals (SHA: 603087)<\/td><\/tr>
New Indication<\/strong><\/td>Moderate\u2011to\u2011severe obstructive sleep apnea (OSA)<\/strong> in obese adults<\/td><\/tr>
Dosing<\/strong><\/td>Once every two weeks<\/strong> (biweekly)<\/td><\/tr>
Prior Development<\/strong><\/td>Phase III (China) \u2013 obesity\/overweight + type 2 diabetes mellitus<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Differentiation<\/h2>\n\n\n\n
Feature<\/th>Bonfaglutide Design<\/th>Competitive Advantage<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>GLP\u20111 receptor agonism<\/strong><\/td>Weight loss \u2192 reduced upper airway collapse; metabolic improvement<\/td><\/tr>
Dosing Frequency<\/strong><\/td>Biweekly (Q2W)<\/strong><\/td>Improved adherence vs. weekly (semaglutide, tirzepatide) or daily options<\/td><\/tr>
Indication Expansion<\/strong><\/td>OSA (sleep apnea) + obesity + T2DM<\/td>Multi\u2011indication metabolic platform<\/strong> \u2013 comprehensive obesity\u2011related comorbidity coverage<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

OSA Market Context & Strategic Positioning<\/h2>\n\n\n\n
Dimension<\/th>Obstructive Sleep Apnea Landscape<\/th>Bonfaglutide Position<\/th><\/tr><\/thead>
Disease Burden<\/strong><\/td>936 million adults<\/strong> globally affected; 70\u201180% undiagnosed<\/strong>; obesity primary risk factor<\/td>Large addressable market with causal obesity link<\/td><\/tr>
Current Standard of Care<\/strong><\/td>CPAP (continuous positive airway pressure) \u2013 adherence 40\u201160%; oral appliances; surgery<\/td>Pharmacological alternative<\/strong> \u2013 addresses root cause (weight) vs. symptom management<\/td><\/tr>
GLP\u20111 OSA Rationale<\/strong><\/td>Weight loss reduces neck circumference and upper airway collapsibility<\/td>Eli Lilly’s tirzepatide<\/strong> (SURMOUNT\u2011OSA) demonstrated 50\u201160% AHI reduction; bonfaglutide follows validated mechanism<\/td><\/tr>
Competitive Dynamics<\/strong><\/td>Tirzepatide (Zepbound) \u2013 Phase III OSA data positive; semaglutide \u2013 OSA trials ongoing<\/td>Biweekly dosing differentiation<\/strong> vs. weekly competitors; China\u2011first development strategy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Outlook<\/h2>\n\n\n\n